Bristol-Myers Demands Changes In Erbitux Deal With ImClone

In a move that seemed to surprise few industry observers, Bristol-Myers Squibb Co. said it wants to restructure the potential $2 billion deal with ImClone Systems Inc. regarding the FDA-stalled Erbitux (cetuximab) for colorectal cancer. (BioWorld Today)